If AI helps speed up drug development, can the FDA keep up?
news.google.commarketplace.org
AI is accelerating drug development timelines, raising questions about whether regulatory frameworks like the FDA can keep pace with faster candidate approval processes and validation requirements.
Why it mattersFor readers following AI in biotech, this highlights a critical gap between technological capability and regulatory capacity that could determine how quickly AI-assisted drugs reach patients.
Read at news.google.com